Swiss pharmaceuticals giant Novartis said Wednesday that strong sales of two of its main blockbuster drugs enabled it to turn in a “good operational performance” in 2017.
Swiss pharmaceuticals giant Novartis said Wednesday that strong sales of two of its main blockbuster drugs enabled it to turn in a “good operational performance” in 2017.